23andMe reported consistent revenue growth, increased R&D, and new verticals. Check out why you should consider a long-term bullish position on ME stock.
(Bloomberg) -- DNA-testing giant 23andMe Holding Co. began clinical trials this week of its first drug developed entirely in-house, a critical step toward the company’s ambitions to make and sell its own therapies.
23andMe Announces the Results of the Completed Redemption of All Outstanding Warrants
SUNNYVALE, Calif., December 28, 2021 - 23andMe Holding Co. , a leading... | December 28, 2021
23andMe, known for its at-home health and ancestry tests, is spending cash raised in its recent public listing on what could be a yearslong process to develop new drugs.
Rising inflationary pressure, a weak job market, and the Fed’s potential tapering could prolong stock market instability in the near term. However, the market is expected to generate some momentum...